Seroatlas · Human Serome Atlas

PRKAR2A

cAMP-dependent protein kinase type II-alpha regulatory subunit

Also known as: KAP2_HUMAN, PRKAR2

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P13861
Gene
PRKAR2A
Ensembl
ENSG00000114302
Chromosome
3
Canonical length
404 aa
Protein class
Plasma proteins, Predicted intracellular proteins
Subcellular location
Vesicles,Centriolar satellite,Basal body,Cytosol,Mid piece

OverviewNCBI Gene

cAMP is a signaling molecule important for a variety of cellular functions. cAMP exerts its effects by activating the cAMP-dependent protein kinase, which transduces the signal through phosphorylation of different target proteins. The inactive kinase holoenzyme is a tetramer composed of two regulatory and two catalytic subunits. cAMP causes the dissociation of the inactive holoenzyme into a dimer of regulatory subunits bound to four cAMP and two free monomeric catalytic subunits. Four different regulatory subunits and three catalytic subunits have been identified in humans. The protein encoded by this gene is one of the regulatory subunits. This subunit can be phosphorylated by the activated catalytic subunit. It may interact with various A-kinase anchoring proteins and determine the subcellular localization of cAMP-dependent protein kinase. This subunit has been shown to regulate protein transport from endosomes to the Golgi apparatus and further to the endoplasmic reticulum (ER). [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

404 residues, UniProt reviewed canonical sequence.

>P13861|PRKAR2A
     1  MSHIQIPPGL TELLQGYTVE VLRQQPPDLV EFAVEYFTRL REARAPASVL PAATPRQSLG
    61  HPPPEPGPDR VADAKGDSES EEDEDLEVPV PSRFNRRVSV CAETYNPDEE EEDTDPRVIH
   121  PKTDEQRCRL QEACKDILLF KNLDQEQLSQ VLDAMFERIV KADEHVIDQG DDGDNFYVIE
   181  RGTYDILVTK DNQTRSVGQY DNRGSFGELA LMYNTPRAAT IVATSEGSLW GLDRVTFRRI
   241  IVKNNAKKRK MFESFIESVP LLKSLEVSER MKIVDVIGEK IYKDGERIIT QGEKADSFYI
   301  IESGEVSILI RSRTKSNKDG GNQEVEIARC HKGQYFGELA LVTNKPRAAS AYAVGDVKCL
   361  VMDVQAFERL LGPCMDIMKR NISHYEEQLV KMFGSSVDLG NLGQ

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PRKAR2A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.39
Highest tissue expression
82 nTPM

Expression across tissuesHPA

Tissue

  • skeletal muscle: 82 nTPM
  • testis: 78 nTPM
  • tongue: 35 nTPM
  • colon: 21 nTPM
  • adipose tissue: 18 nTPM
  • rectum: 17 nTPM

Single-cell type

  • late spermatids: 1,852 nCPM
  • early spermatids: 1,049 nCPM
  • myonuclei: 323 nCPM
  • neutrophils: 298 nCPM
  • late primary spermatocytes: 216 nCPM
  • pituicytes/fscs: 200 nCPM

Immune cell

  • non-classical monocyte: 11 nTPM
  • neutrophil: 8.5 nTPM
  • eosinophil: 7.5 nTPM
  • NK-cell: 7.2 nTPM
  • basophil: 6.7 nTPM
  • myeloid DC: 6.6 nTPM

Brain region

  • hypothalamus: 43 nTPM
  • medulla oblongata: 40 nTPM
  • spinal cord: 38 nTPM
  • pons: 38 nTPM
  • white matter: 38 nTPM
  • choroid plexus: 37 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.52
gnomAD pLI
0.12
gnomAD missense Z
1.26
DepMap mean gene effect
-0.17
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of PRKAR2A in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PRKAR2A as an antibody target. Whether an autoantibody or antibody against PRKAR2A could matter depends on whether native PRKAR2A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PRKAR2A is annotated at the cell surface, where native PRKAR2A is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label PRKAR2A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/PRKAR2A. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...